Fox Chase Cancer Center Patent applications |
Patent application number | Title | Published |
20150353928 | Genes Contributing to Survival of Cancer Cells - The invention relates to methods of inhibiting the growth or proliferation of a cell, the method comprising reducing the expression or activity of at least one gene in the cell selected from the group consisting of BLOC1S1, CDC2L1, CNOT1, CYR61, DDX54, EIF3I, FANCG, FBP1, IER2, KIF1A, LCK, NR2F1, PNRC1, POLR2A, POLR2B, POLR2C, PRPF6, PSMB4, PSMC5, PSMD1, PTK7, RPS2, SCNN1A, SF3A3, TAF2, TOB1, TSC22D4. | 12-10-2015 |
20150119263 | CARBON NANOTUBE BIOSENSORS AND RELATED METHODS - Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analytes contacted to the devices, including the presence of markers for prostate cancer and Lyme disease. | 04-30-2015 |
20140357650 | NOVEL FAP INHIBITORS - The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders. | 12-04-2014 |
20140272947 | METHODS AND COMPOSITIONS FOR SCREENING MODULATORS OF ONCOGENE-INDUCED SENESCENCE - A high-throughput method for identifying a compound or biomolecule that modulates cell senescence involves simultaneously measuring in a cell population exposed to the test compound or biomolecule, the expression of a senescence marker and cell number, wherein each well contains a single test compound; and determining from said simultaneous measurements whether the test compound increases or decreases cell senescence. In various embodiments, the method is useful is identifying compounds that delay the aging process of normal healthy cells, or identifying a compound useful as a tumor suppressor or identifying a compound useful in the treatment of cancer. | 09-18-2014 |
20140100431 | METHOD FOR INSERTING MEDICAL INSTRUMENT - To reliably fix a medical instrument to a body wall by easy operation without causing increased costs and complicated configuration. For inserting a trocar as a medical instrument which can be pierced into a body cavity, a front end of the trocar is inserted into a body wall along a first direction having a specified angle with respect to an exterior surface of the body wall, and then the front end of the trocar is inserted into the body wall along a second direction whose angle with the exterior surface of the body wall is acuter than that of the first direction. As a result, the trocar is reliably fixed with large resistance received from the body wall. | 04-10-2014 |
20140100421 | METHOD OF PLACING MEDICAL INSERTION INSTRUMENTS IN BODY CAVITY - An endoscope and an illuminator are safely placed in a body cavity without generating a noticeable postoperative scar. A method of placing medical insertion instruments into a body cavity includes a first step of inserting, into the body cavity through a first opening formed on a body wall, an endoscope together with a first illuminator; and a second step of inserting, into the body cavity through a second opening formed at a position different from the first opening, a second illuminator. Preferably, the method further includes a third step of pulling out the first illuminator from the first opening and inserting the first illuminator into the body cavity through a third opening formed at a position different from the first and second openings. | 04-10-2014 |
20140087005 | MODULATORS OF HSP70/DNAK FUNCTION AND METHODS OF USE THEREOF - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 03-27-2014 |
20140050665 | METHOD FOR THE TREATMENT OR PROPHYLAXIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) AND ANIMAL MODEL FOR USE IN LAM RESEARCH - Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection. | 02-20-2014 |
20130331294 | EGFR/NEDD9/TGF-BETA INTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS - Compositions and methods for the treatment and diagnosis of cancer are disclosed. | 12-12-2013 |
20130202603 | BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF - Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. | 08-08-2013 |
20130108547 | Recombinantly Produced Antibodies Targeting ErbB Signaling Molecules and Methods of Use Thereof for the Diagnosis and Treatment of Disease | 05-02-2013 |
20130064882 | Compositions and Methods for the Prevention of Cancer in High Risk Patients - This relates to the prevention of cancer initiation. More specifically, the invention provides compositions and methods useful for altering the genetic signature in breast tissue, said alteration being correlated with a reduced risk for the development of breast cancer. | 03-14-2013 |
20130058935 | ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 7R - Antibodies that specifically bind to an epitope on the extracellular domain of TEM7R are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided. The antibodies may be used in methods for treating tumors and for inhibiting angiogenesis in tumors. | 03-07-2013 |
20130040386 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 02-14-2013 |
20130004504 | METHOD OF MODULATING PHENYLALANINE HYDROXYLASE STRUCTURE AND FUNCTION - A method of affecting a multimeric protein comprising an equilibrium of assembly states, each assembly having a plurality of units, wherein each of the units comprises a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms under four conditions, wherein the method comprising: applying to the multimeric protein a composition comprising a compound adapted to affect formation of an active form of the multimeric protein; associating the composition with an active form of the multimeric protein; and promoting the multimeric protein to assemble into the active form, thereby affecting the multimeric protein to form the active form, wherein the multimeric protein is phenylalanine hydroxylase. | 01-03-2013 |
20120258937 | Targeting Estrogen Receptors in the Treatment of Lymphangioleiomyomatosis - Methods for inhibiting estrogen hormone-induced pulmonary metastasis of smooth muscle cells that are capable of pulmonary metastasis comprise antagonizing the estradiol receptor on the smooth muscle cells such that pulmonary metastasis of the cells is inhibited. | 10-11-2012 |
20120245173 | INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1 - Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided. | 09-27-2012 |
20120084011 | METHODS FOR MANAGING CANCER PATIENT CARE - Methods for managing the care of a cancer patient are provided. Generally, the methods comprise calculating a risk score from characteristics obtained from a cancer patient with a plurality of nomograms comprising the characteristics and a plurality of competing risk factors, using a program to calculate risk scores; determining the patient's prognosis based on the risk score; and treating the patient with a regimen capable of improving the prognosis of a cancer patient having substantially the same risk score. Systems and computer readable media for practicing the methods are also provided. | 04-05-2012 |
20110307967 | TetO-p16 Transgenic Mice - Mice comprising a human p16 transgene operably linked to an inducible promoter and capable of controlled expression of p16 are provided. Also provided are cells, tissues, and organs obtainable from such mice, and methods for producing p16 transgenic mice. | 12-15-2011 |
20110207816 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 08-25-2011 |
20110198516 | SHIELDING FOR COMPACT RADIATION SOURCES - Disclosed are radiation shields substantially enclosing a source of polyenergetic positive ions. The shielding layers are spatially arranged to absorb substantially all unwanted radiation arising directly or indirectly from the polyenergetic positive Also disclosed are methods of shielding unwanted radiation leaking from a system providing a therapeutic dose of polyenergetic positive radiation, as well as shielded polyenergetic positive ion selection systems. | 08-18-2011 |
20110189125 | Modulators of HSP70/DnaK Function and Methods of Use Thereof - Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed. | 08-04-2011 |
20110172107 | ASSAY FOR IDENTIFYING AGENTS THAT MODULATE EPIGENETIC SILENCING, AND AGENTS IDENTIFIED THEREBY - A high throughput RNAi-based assay for identify factors involved in maintaining epigenetic silencing is disclosed. The assay measures reactivation of a silent reporter gene in cells, resulting from RNAi-based knockdown in target mRNA. RNAi-based screening of these silent reporter cells has identified known enzymes that place or remove epigenetic marks on histones, as well as non-enzymatic proteins that function in silencing or in transfer of marks during S-phase. In addition, the screen has been used to identify a number of novel gene products involved in epigenetic silencing, which are also disclosed. | 07-14-2011 |
20110110925 | Compositions and Methods for the Treatment and Diagnosis of Cancer - Compositions and methods for the diagnosis and treatment of cancer, particularly T-ALL, are disclosed. | 05-12-2011 |
20100320394 | METHODS AND SYSTEMS FOR INCREASING THE ENERGY OF POSITIVE IONS ACCELERATED BY HIGH-POWER LASERS - The energy of positive ions accelerated in laser-matter interaction experiments can be significantly increased by providing a plurality of laser pulses, e.g., through the process of splitting the incoming laser pulse, to form multiple laser-matter interaction stages. From a thermodynamic point of view, the splitting procedure can be viewed as an effective way of increasing the efficiency of energy transfer from the laser light to positive ions, which energy peaks for processes having the least amount of entropy gain. A 100% increase in the energy efficiency is achieved for a six-stage laser positive ion accelerator compared to a single-stage laser positive ion accelerator. | 12-23-2010 |
20100086996 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 04-08-2010 |
20100086486 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ, TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 04-08-2010 |
20090230318 | TARGET DESIGN FOR HIGH-POWER LASER ACCELERATED IONS - Methods for designing a laser-accelerated ion beam are disclosed. The methods include modeling a system including a heavy ion layer, an electric field, and high energy light positive ions having a maximum light positive ion energy, correlating physical parameters of the heavy ion layer, the electric field, and the maximum light positive ion energy using the model, and varying the parameters of the heavy ion layer to optimize the energy distribution of the high energy light positive ions. One method includes analyzing the acceleration of light positive ions, for example protons, through interaction of a high-power laser pulse with a double-layer target using two-dimensional particle-in-cell (PIC) simulations and a one-dimensional analytical model. The maximum energy acquired by the accelerated light positive ions, e.g., protons, in this model depends on the physical characteristics of the heavy-ion layer—the electron-ion mass ratio and effective charge state of the ions. The hydrodynamic equations for both electron and heavy ion species solved and the test-particle approximation for the protons is applied. It was found that the heavy ion motion modifies the longitudinal electric field distribution, thus changing the acceleration conditions for the light positive ions. | 09-17-2009 |
20090050819 | Laser-Accelerated Proton Therapy Units And Superconducting Electromagnet Systems For Same - Compact particle selection and collimation devices are disclosed for delivering beams of protons with desired energy spectra. These devices are useful with laser-accelerated proton therapy systems, in which the initial protons have broad energy and angular distributions. Superconducting magnet systems produce a desired magnetic field configuration to spread the protons with different energies and emitting angles for particle selection. The simulation of proton transport in the presence of the magnetic field shows that the selected protons are successfully refocused on the beam axis after passing through the magnetic field with the optimal magnet system. Dose distributions are also provided using Monte Carlo simulations of the laser-accelerated proton beams for radiation therapy applications. | 02-26-2009 |
20090048324 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 02-19-2009 |
20080286847 | ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES - A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary surface and a second complementary surface and wherein the first complementary surface of one unit is associated with the second complementary surface of another unit, provided that the assembly is at least one of different quaternary isoforms on a condition that in the multimeric protein (1) a structure of each of the units determines a structure of the different quaternary isoforms, (2) the units are in the equilibrium and (3) the structure of the different quaternary isoforms influences a function of the multimeric protein. | 11-20-2008 |
20080247990 | GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES - The invention provides a natural killer cell, NK-92, modified to express a CD16 receptor or an inhibitory killer cell immunoglobulin-like receptor (KIR) on a surface of the cell. In examples, the NK-92 cell is further modified to co-express an associated accessory signaling protein such as FcεRI-γ or TCR-ζ, chemokines, or cytokines such as interleukin-2 (IL-2) or interleukin-15 (IL-15). Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells. | 10-09-2008 |